FDA Approves Pembrolizumab-Belzutifan Combo for High-Risk Kidney Cancer Post-Surgery
On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved the combination of pembrolizumab (Keytruda) and belzutifan (Welireg) as an adjuvant treatment for adult patients with clear cell renal cell carcinoma (ccRCC) who are at intermediate-high or high risk of disease recurrence following surgical nephrectomy (with or without removal of metastatic lesions).
This represents a major therapeutic milestone: it is the first combination regimen shown to outperform pembrolizumab monotherapy—the previous standard of care—in the adjuvant setting for kidney cancer.
Clinical Data from LITESPARK-022
The approval is backed by robust results from the Phase 3 LITESPARK-022 clinical trial, which enrolled 1,841 patients who had undergone nephrectomy and had no residual disease but carried a high estimated risk of relapse. Participants were randomized to receive either the combination of pembrolizumab plus belzutifan or pembrolizumab plus a placebo.
- Efficacy: At a median follow-up of 28.4 months, patients treated with the pembrolizumab-belzutifan combination demonstrated a 28% reduction in the risk of recurrence, metastasis, or death compared to those receiving pembrolizumab alone.
- Two-Year Recurrence-Free Survival (RFS): Approximately 81% of patients in the combination arm remained free from cancer at two years, compared to 74% of those in the pembrolizumab monotherapy control arm.
- Formulation Flexibility: The approval also covers the subcutaneous formulation of pembrolizumab (Keytruda Qlex), administered in combination with oral belzutifan, which may enhance treatment convenience and patient adherence.
Mechanism of Action
The regimen combines two complementary mechanisms:
- Pembrolizumab: An immune checkpoint inhibitor that blocks the PD-1 pathway, restoring the body's anti-tumor immune response.
- Belzutifan: A first-in-class small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α). HIF-2α is a transcription factor that is aberrantly stabilized and overexpressed in the vast majority of ccRCC tumors due to mutations in the von Hippel-Lindau (VHL) tumor suppressor gene. Its inhibition blocks tumor angiogenesis, cell proliferation, and immune evasion.
Verbatim Quotes
- Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber:
“This combination therapy offers an enhanced strategy compared with pembrolizumab alone, aiming to reduce the risk of recurrence and improve long-term cancer control.”